PT  - JOURNAL ARTICLE
AU  - Sarkar, Gayatri
AU  - Alattar, May
AU  - Brown, Rebecca J.
AU  - Quon, Michael J.
AU  - Harlan, David M.
AU  - Rother,  Kristina I.
TI  - Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
AID  - 10.2337/dc13-1473
DP  - 2014 Mar 01
TA  - Diabetes Care
PG  - 666--670
VI  - 37
IP  - 3
4099  - http://care.diabetesjournals.org/content/37/3/666.short
4100  - http://care.diabetesjournals.org/content/37/3/666.full
SO  - Diabetes Care2014 Mar 01; 37
AB  - OBJECTIVE Exenatide treatment improves glycemia in adults with type 2 diabetes and has been shown to reduce postprandial hyperglycemia in adolescents with type 1 diabetes. We studied the effects of exenatide on glucose homeostasis in adults with long-standing type 1 diabetes.RESEARCH DESIGN AND METHODS Fourteen patients with type 1 diabetes participated in a crossover study of 6 months' duration on exenatide (10 μg four times a day) and 6 months off exenatide. We assessed changes in fasting and postprandial blood glucose and changes in insulin sensitivity before and after each study period.RESULTS High-dose exenatide therapy reduced postprandial blood glucose but was associated with higher fasting glucose concentrations without net changes in hemoglobin A1c. Exenatide increased insulin sensitivity beyond the effects expected as a result of weight reduction.CONCLUSIONS Exenatide is a promising adjunctive agent to insulin therapy because of its beneficial effects on postprandial blood glucose and insulin sensitivity in patients with type 1 diabetes.